11,457 Shares in ShockWave Medical, Inc. (NASDAQ:SWAV) Bought by Granahan Investment Management LLC

Granahan Investment Management LLC bought a new position in ShockWave Medical, Inc. (NASDAQ:SWAVGet Rating) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 11,457 shares of the company’s stock, valued at approximately $2,376,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Candriam Luxembourg S.C.A. purchased a new position in shares of ShockWave Medical during the 4th quarter valued at about $2,568,000. Lincoln National Corp bought a new position in ShockWave Medical during the first quarter valued at approximately $211,000. Level Four Advisory Services LLC lifted its holdings in shares of ShockWave Medical by 21.2% in the 1st quarter. Level Four Advisory Services LLC now owns 4,426 shares of the company’s stock worth $918,000 after acquiring an additional 773 shares during the last quarter. Wealth Dimensions Group Ltd. purchased a new stake in shares of ShockWave Medical in the 1st quarter valued at $207,000. Finally, HM Payson & Co. bought a new position in shares of ShockWave Medical during the 4th quarter valued at $77,000. 95.40% of the stock is currently owned by hedge funds and other institutional investors.

ShockWave Medical Trading Down 2.1 %

NASDAQ:SWAV opened at $287.14 on Monday. The company has a 50-day moving average price of $248.20 and a 200-day moving average price of $201.84. ShockWave Medical, Inc. has a 12 month low of $113.36 and a 12 month high of $314.90. The company has a current ratio of 5.32, a quick ratio of 4.41 and a debt-to-equity ratio of 0.02. The stock has a market cap of $10.28 billion, a price-to-earnings ratio of 196.67 and a beta of 1.06.

ShockWave Medical (NASDAQ:SWAVGet Rating) last posted its earnings results on Monday, August 8th. The company reported $0.68 EPS for the quarter, topping the consensus estimate of $0.43 by $0.25. ShockWave Medical had a net margin of 15.11% and a return on equity of 21.25%. The firm had revenue of $120.70 million during the quarter, compared to analysts’ expectations of $107.51 million. During the same period last year, the company posted ($0.01) EPS. The company’s quarterly revenue was up 115.5% compared to the same quarter last year. Equities analysts predict that ShockWave Medical, Inc. will post 2.57 EPS for the current year.

Insider Transactions at ShockWave Medical

In other news, Director Maria Sainz sold 650 shares of the firm’s stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $295.00, for a total value of $191,750.00. Following the completion of the sale, the director now directly owns 5,316 shares of the company’s stock, valued at approximately $1,568,220. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director Maria Sainz sold 650 shares of the stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $295.00, for a total value of $191,750.00. Following the completion of the transaction, the director now directly owns 5,316 shares in the company, valued at approximately $1,568,220. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Frank T. Watkins sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, June 21st. The shares were sold at an average price of $161.43, for a total transaction of $484,290.00. Following the sale, the director now owns 17,802 shares of the company’s stock, valued at $2,873,776.86. The disclosure for this sale can be found here. In the last ninety days, insiders sold 109,012 shares of company stock valued at $29,770,262. Company insiders own 3.90% of the company’s stock.

Wall Street Analyst Weigh In

SWAV has been the topic of several recent research reports. Oppenheimer lowered shares of ShockWave Medical from a “market perform” rating to an “underperform” rating and set a $165.00 target price on the stock. in a report on Tuesday, September 6th. Piper Sandler increased their target price on shares of ShockWave Medical from $278.00 to $338.00 and gave the company an “overweight” rating in a report on Monday, August 29th. Wells Fargo & Company increased their target price on shares of ShockWave Medical from $176.00 to $255.00 and gave the company an “overweight” rating in a report on Tuesday, August 9th. Morgan Stanley increased their target price on shares of ShockWave Medical from $201.00 to $255.00 and gave the company an “equal weight” rating in a report on Tuesday, August 9th. Finally, Canaccord Genuity Group increased their target price on shares of ShockWave Medical from $232.00 to $256.00 and gave the company a “buy” rating in a report on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, ShockWave Medical presently has a consensus rating of “Moderate Buy” and a consensus price target of $246.50.

ShockWave Medical Profile

(Get Rating)

ShockWave Medical, Inc, a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD.

Read More

Want to see what other hedge funds are holding SWAV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ShockWave Medical, Inc. (NASDAQ:SWAVGet Rating).

Institutional Ownership by Quarter for ShockWave Medical (NASDAQ:SWAV)

Receive News & Ratings for ShockWave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShockWave Medical and related companies with MarketBeat.com's FREE daily email newsletter.